Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

PURPOSE: Everolimus improved median progression-free survival by 6.4 months in patients with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the RADIANT-3 study. Here, we present the final overall survival (OS) data and data on the impact of biomarkers on OS from the RADIANT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Yao, James C., Pavel, Marianne, Lombard-Bohas, Catherine, Van Cutsem, Eric, Voi, Maurizio, Brandt, Ulrike, He, Wei, Chen, David, Capdevila, Jaume, de Vries, Elisabeth G.E., Tomassetti, Paola, Hobday, Timothy, Pommier, Rodney, Öberg, Kjell
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791842/
https://ncbi.nlm.nih.gov/pubmed/27621394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.68.0702
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados